The past few years have been challenging for the biotech.
The cardiology landscape is rapidly evolving. Novel risk factors and new tools are reshaping CV risk assessment and ...
CRISPR Therapeutics' CASGEVY gene-editing therapy targets severe SCD and TDT. Click here to read why CRSP stock is rated as a Buy.
We asked 12 scientists, artists, and thought leaders to share how AI enabled them to create, explore, or understand something ...
3d
CRISPR Therapeutics AG (CRSP) Presents at Citi's 2026 Virtual Oncology Leadership Summit Transcript
Citi's 2026 Virtual Oncology Leadership Summit February 18, 2026 10:45 AM ESTCompany ParticipantsSamarth Kulkarni - CEO ...
4d
Gene Editing Has Struggled To Go Commercial. This Nobel Laureate Has A $1 Billion Plan To Fix That.
Crispr’s ability to cut genetic code like scissors has just started to turn into medicines. Now, gene editing pioneer ...
Following over a year of slow uptake, Vertex Pharmaceuticals and CRISPR Therapeutics expect Casgevy revenues to nearly triple ...
The idea of self-amplifying gene editing is to get cells to pass on packages of CRISPR machinery to their neighbours, boosting the effect ...
Scientists are testing an entirely new way to fight heart disease: whether gene editing might offer a one-time fix for high cholesterol.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results